Rolando Gutierrez-Esteinou
CIK 1860581 · View on SEC EDGAR ↗
First SEC filing: March 16, 2023 · Latest: March 16, 2023
On this page
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 14, 2023 | ATAI | A | 200,000 | — | — | 200,000 Direct | — | Acquired | |
| March 14, 2023 | ATAI | A | 500,000 | — | — | 500,000 Direct | — | Acquired | |
| March 2, 2022 | ATAI | A | 206,950 | — | — | 206,950 Direct | — | Acquired | |
| Dec. 24, 2021 | ATAI | A | 0 | — | — | 0 Direct | — | Acquired | |
| Dec. 24, 2021 | ATAI | A | 325,000 | — | — | 325,000 Direct | — | Acquired | |
| June 17, 2021 | ATAI | A | 752,311 | — | — | 752,311 Direct | — | Acquired |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 14, 2023 | ATAI | Restricted Stock Unit | Common Shares (200,000) | — | — | 200,000 | Acquired |
| March 14, 2023 | ATAI | Stock Option | Common Shares (500,000) | $1.18 | March 14, 2033 | 500,000 | Acquired |
| March 2, 2022 | ATAI | Stock Option | Common Shares (206,950) | $5.65 | March 1, 2032 | 206,950 | Acquired |
| Dec. 24, 2021 | ATAI | Stock Option | Common Shares | — | — | 0 | Acquired |
| Dec. 24, 2021 | ATAI | Stock Option | Common Shares (325,000) | $7.72 | Dec. 23, 2031 | 325,000 | Acquired |
| June 17, 2021 | ATAI | Stock Option | Common Shares (752,311) | $15.00 | June 17, 2031 | 752,311 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CIK 1840904
M.D. Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $330,000 | $118,041 | $236,000 | $440,000 | — | — | $349,441 | $1,473,481 |
| 2021 | $420,000 | $195,378 | — | $10,753,988 | — | — | — | $11,369,366 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.